Skip to main content

Table 2 Summary of phase II-III trials of Irinotecan-based doublet regimen on advanced NSCLC as first-line chemotherapy (2006–1990)*

From: Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

Author

N

Races

Regimen

Efficacy

Toxicity

Median OS (month)

Median PFS (month)

RR (%)

Grade 3/ 4 Neut. (%)

Grade 3/4 Diarrea (%)

Asian trials

Saito H et al.[23] 2006

27

Japanese

Irinotecan 60 mg/m2 day 1, 8, Cisplatin 60 mg/ m2 day 1, q 21 days

12.1

NR

30.0

60.0

22.0

Hino M et a[l24] 2006

39

Japanese

Irinotecan 60 mg/m2 on days 1, 8, 15, Cisplatin 30 mg/ m2 day 1, 8, 15, q 28 days

12.8

2.1

33.3

15.4

15.4

Zhang XR et al.[25] 2006

24

Chinese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/ m2 day 1, q 28 days

NR

NR

29.2

17.1

5.7

Fukuda M et al.[26] 2004

59

Japanese

Irinotecan 50 mg/m2 on days 1, 8 and 15, Carboplatin AUC 5, q 28 days

10.0

4.0

34.0

60.0

7.0

Yamamoto N et al.[14] 2004

57

Japanese

Irinotecan 60mg/m2 day 1, 8, Docetaxel 60mg/m2 day 8, q 21 days

10.7

4.2

32.0

84.0

16.0

Ichiki M et al.[27] 2003

44

Japanese

Irinotecan 80 mg/m2 day 1, 8, 15, Ifosfamide 1.5 g/m2 day 1 to 3, q 28 days

12.5

5.3

29.5

38.6

6.8

Negoro S et al.[13] 2003

133

Japanese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

11.7

4.9

43.3

37.0 (grade 4)

12.0

Takeda K et al.[28] 2002

36

Japanese

Irinotecan 50 mg/m2 day 1, 8, 15, Carboplatin AUC 5 day 1, q 28 days

10.2

NR

25.0

76.5

5.9

Ueoka H et al.[30] 2001

44

Japanese

Irinotecan 50 mg/m2 day 1, 8, Cisplatin 60 mg/m2 day 1, 8, q 28days

12.5

NR

48

70.5

25

Nagao K et al.[29] 2000

69

Japanese

Irinotecan 65 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

10.3

NR

47.8

80.3

18.8

Takiguchi Y et al.[18] 2000

104

Japanese

Irinotecan 60mg/m2 day 1, 8, 15, Cisplatin 80mg/m2 day 1, q 28 days

10.5

NR

29.0

50.0 (grade 4)

13.0

Masuda N et al.[31] 1998

69

Japanese

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

10.3

NR

52.0

80

19

Non-Asian trials

Cardenal F et al.[37] 2003

73

Spanish

Irinotecan 200 mg/m2 day 1, Cisplatin 80 mg/m2 day 1, q 21 days

8.2

3.9

24.7

NR

29.0

Jagasia MH et al.[38] 2001

50

Americans

Irinotecan 65 mg/m2 and Cisplatin 30 mg/ m2 day 1, 8, 15, 21, q 42 days

11.6

6.9

36.0

26.0

26.0

DeVore RF et al.[39] 1999

52

Americans

Irinotecan 60 mg/m2 day 1, 8, 15, Cisplatin 80 mg/m2 day 1, q 28 days

9.9

5.1

28.8

46.1

17.3

Pillot GA et al.[32] 2006

42

Americans

Irinotecan 200 mg/m2 day 1 , Carboplatin AUC 5 day 1, q 21days

11.7

6.9

14.0

62.0

5.0

Ziotopoulos P et al.[33] 2005

39

Greeks

Irinotecan 200 mg/m2 day 1, Docetaxel 80 mg/m2 day 1, q 21 days

10.8

3.0

23.0

28.2

23.1

Stathopoulos GP et al.[34] 2005

52

Greeks

Irinotecan 125 mg/m2 day 1, 8, Paclitaxel 135 mg/m2 day 1, q 21 days

NR

6.0

41.0

NR

NR

Murren JR et al.[35] 2005

23

Americans

Irinotecan 50 mg/m2 and Paclitaxel 75 mg/m2 on days 1 and 8 , q 21 days

9.2

2.8

9.0

26.0

5.0

Raez LE et al.[36] 2004

14

Irish

Irinotecan 50mg/m2 day 1, 8, 15, Docetaxel 50mg/m2 day 2, q 28 days

11.0

NR

7.0

21.0

0

Rocha Lima CM et al.[19] 2004

39

Americans

Irinotecan 100 mg/ m2 day 1, Gemcitabine 1000 mg/ m2 day 1, 8, q 21 days

8.0

3.5

12.8

26.0

13.0

  1. NR not reported, Ad. adenocarcinoma, Neut. neutropenia
  2. *The literature was selected according to the criteria as follows: (1) NSCLC patients with previously untreated with chemotherapy; (2) treated with irinotecan-based doublet regimen; (3) prospective clinical trials Phase II and III.